Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies.

"Conflicts of interest: The University of Glasgow, which employs N.N.L. and C.G. has received research grant funding from Roche Diagnostics, AstraZeneca and Boehringer Ingelheim (outside the submitted work). N.N.L. has received speaker’s fees/advisory board fees from Roche, Pharmacosmos, AstraZeneca and Novartis. The UMCG, which employs S.d.W. and R.A.d.B., has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche (outside the submitted work). R.A.d.B. received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche (outside the submitted work)."

"Funding N.N.L. is supported by a British Heart Foundation Centre of Research Excellence Grant (RE/18/6/34217). R.A.d.B. is supported by the European Research Council (ERC CoG 818715), by the Netherlands Heart Foundation (grants 2017–21; 2017–11; 2018–30; 2020B005), and by the Fondation LeDucq (Cure-PLaN)."